Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber.

Meyer, W; Narkus, A; Salapatek, A M; Häfner, D

Meyer, W; Narkus, A; Salapatek, A M; Häfner, D.

Affiliation

Meyer W; Medical Department Allergopharma GmbH & Co. KG, Reinbek, Germany.

Allergy ; 68(6): 724-31, 2013 Jun.

Article in En | MEDLINE | ID: mdl-23621350

Subject(s)

Allergens/administration & dosage; Antigens, Plant/administration & dosage; Desensitization, Immunologic/methods; Rhinitis, Allergic, Seasonal/therapy; Adolescent; Adult; Aged; Allergens/therapeutic use; Analysis of Variance; Antigens, Plant/therapeutic use; Atmosphere Exposure Chambers; Desensitization, Immunologic/instrumentation; Dose-Response Relationship, Immunologic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Recombinant Proteins/administration & dosage; Recombinant Proteins/therapeutic use; Rhinitis, Allergic, Seasonal/immunology; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 Database: MEDLINE Main subject: Allergens / Rhinitis, Allergic, Seasonal / Desensitization, Immunologic / Antigens, Plant Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Allergy Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google